Cargando…

Role of hormonal therapy for prostate cancer: perspective from Japanese experiences

Hormonal therapy has been playing an important role in the treatment of prostate cancer. However, it has recently been the subject of criticism that it shows minimal effectiveness, it may reduce patients’ quality of life, and induce adverse effects. On the other hand, next-generation hormonal drugs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Namiki, Mikio, Ueno, Satoru, Kitagawa, Yasuhide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708248/ https://www.ncbi.nlm.nih.gov/pubmed/26813083 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.07.03

Ejemplares similares

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia
por: Kitagawa, Yasuhide, et al.
Publicado: (2015)

Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer
por: Miwa, Sotaro, et al.
Publicado: (2013)

Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)
por: Ueno, Satoru, et al.
Publicado: (2018)

Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
por: Kitagawa, Yasuhide, et al.
Publicado: (2013)

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan
por: Kitagawa, Yasuhide, et al.
Publicado: (2014)

Metastatic Urothelial Carcinoma of the Prepuce and Glans Penis: Suspected Implantation of Non-Muscle-Invasive Bladder Cancer via Urine
por: Makino, Tomoyuki, et al.
Publicado: (2014)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer
por: Suzuki, Hiroyoshi, et al.
Publicado: (2019)

Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score
por: Kawahara, Takashi, et al.
Publicado: (2016)

Inflammatory Myofibroblastic Tumor of the Urinary Bladder with Benign Pelvic Lymph Node Enlargement: A Case Report
por: Machioka, Kazuaki, et al.
Publicado: (2014)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old
por: Blas, Leandro, et al.
Publicado: (2021)

Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2015)

Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies
por: Garg, Manish, et al.
Publicado: (2013)

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer
por: Miura, Yuji, et al.
Publicado: (2019)

Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial
por: Konaka, Hiroyuki, et al.
Publicado: (2012)

Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study
por: Nakajima, Kenichi, et al.
Publicado: (2021)

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
por: Akaza, Hideyuki, et al.
Publicado: (2016)

Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2015)

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer
por: Sugino, Fumiya, et al.
Publicado: (2023)

Particle therapy for prostate cancer: The past, present and future
por: Ishikawa, Hitoshi, et al.
Publicado: (2019)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study
por: Kawahara, Takashi, et al.
Publicado: (2020)

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score
por: Akaza, Hideyuki, et al.
Publicado: (2013)

Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study
por: Kandori, Shuya, et al.
Publicado: (2016)

Sperm cryopreservation before definitive therapy for early‐stage prostate cancer: A single institution experience
por: Miyoshi, Yasuhide, et al.
Publicado: (2022)

Hormone refractory prostate cancer: Current understanding and future perspectives
por: Khochikar, Makarand
Publicado: (2007)

Cardiovascular effects of hormone therapy for prostate cancer
por: Lester, Jason F, et al.
Publicado: (2015)

Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment
por: Uemura, Hiroji, et al.
Publicado: (2021)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

Prevalence of human papillomavirus infection in the oropharynx and urine among sexually active men: a comparative study of infection by papillomavirus and other organisms, including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma spp., and Ureaplasma spp
por: Nakashima, Kazufumi, et al.
Publicado: (2014)

Report of the third Asian Prostate Cancer study meeting
por: Lojanapiwat, Bannakij, et al.
Publicado: (2019)

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
por: Sasaki, Takeshi, et al.
Publicado: (2021)

Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate
por: Saad, Fred
Publicado: (2022)

The side effects of hormonal therapy at the patients with prostate cancer
por: Ziółkowska, Ewa, et al.
Publicado: (2013)

Addressing Cardiovascular Risk of Prostate Cancer Hormonal Therapy
por: Ryan, Charles J., et al.
Publicado: (2020)

Future perspectives of prostate cancer therapy
por: Gururajan, Murali, et al.
Publicado: (2012)

Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan
por: Suzuki, Kazuhiro, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ptbh0d17j39arj1c2lme6tfo91